Cipla Limited has entered into definitive agreements to acquire a 100% stake in Inzpera Healthsciences Limited. Following the acquisition, Inzpera will become a wholly-owned subsidiary of Cipla. The enterprise value of Inzpera is INR 120 crores, with the purchase consideration adjusted to approximately INR 110.65 crores pending final adjustments at closing.
Acquisition Overview
Cipla Limited has announced its strategic decision to acquire a 100% stake in Inzpera Healthsciences Limited. This acquisition will result in Inzpera becoming a wholly-owned subsidiary of Cipla, enhancing Cipla’s portfolio and market presence.
Deal Terms and Valuation
The enterprise value of Inzpera is valued at INR 120 crores. The final purchase consideration is approximately INR 110.65 crores, subject to customary adjustments at the closing of the transaction. This consideration covers the acquisition of both equity shares and non-convertible redeemable preference shares.
About Inzpera Healthsciences
Inzpera Healthsciences Limited, incorporated in 2016, is focused on developing, manufacturing, and marketing differentiated pediatric pharmaceutical and wellness products. The acquisition aims to combine Inzpera’s product portfolio with Cipla’s strong distribution network.
Strategic Rationale
This acquisition is a strategic move to combine Inzpera’s extensive range of pediatric pharmaceutical and wellness products with Cipla’s established distribution network and operational capabilities. The company expects this acquisition to be completed within one month from November 3, 2025.
Inzpera’s Financial Performance
Key turnover figures for the last three financial years are as follows:
- FY 2024-25: INR 26.75 crores
- FY 2023-24: INR 22.05 crores
- FY 2022-23: INR 20.76 crores
Source: BSE
